Bio-Rad Laboratories Inc - Company Profile
Powered by 
All the sales intelligence you need on Bio-Rad Laboratories Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Bio-Rad Laboratories Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Bio-Rad Laboratories Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
Bio-Rad Laboratories Inc (Bio-Rad) develops, manufactures, and markets instruments, software, consumables, and reagents for the life science research and clinical diagnostics markets. Its products include antibodies, autoimmune testing kits, blood typing and antibody detection systems, cell isolation and analysis tools, and digital PCR, among others. The company’s products find applications in bioprocess analytics, cell research, gene expression analysis, immunology, and mutation detection, among others. It serves university and research institutions, hospitals, public health and commercial laboratories, diagnostic manufacturers, and companies in the biotechnology, pharmaceutical, chemical, and food industries. Bio-Rad offers its products through direct sales channels, distributors, agents, brokers, and resellers. The company has operations in the US, Germany, France, China, and Singapore, among others. Bio-Rad is headquartered in Hercules, California, the US.
Headquarters
United States of America
Address
1000 Alfred Nobel Dr, Hercules, California, 94547
Website
www.bio-rad.com
Telephone
1 510 7247000
No of Employees
7,450
Industry
Medical Equipment
Ticker Symbol & Exchange
BIO (NYSE)
Revenue (2024)
$2.6B
0.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
141.2%
(2024 vs 2023)
Market Cap*
$8.0B
Net Profit Margin (2024)
XYZ
140.9%
(2024 vs 2023)
* As of and is in US$
Bio-Rad Laboratories Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Life Science Research: | Process Separation: | Droplet Digital |
| Genomics | Affinity Resins | Vericheck ddPCR |
| Next-Generation Sequencing | Ion Exchange Resins | GraftAssure |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | New Products/Services | In July, the company introduced the QX700 System-compatible Vericheck ddPCR Kit portfolio for critical quality control (QC) workflows. |
| 2026 | Regulatory Approval | In June, the company's EZ-Check Kits for detecting Listeria spp. and Listeria monocytogenes in food and environmental samples received approval from MicroVal. |
| 2026 | New Products/Services | In April, the company launched eight antibodies specific to romosuzumab (Evenity), burosumab (Crysvita), ixekizumab (Taltz), elotuzumab (Empliciti), isatuximab (Sarclisa), nirsevimab (Beyfortus), and tremelimumab (Imjudo). |
Competitor Comparison
| Key Parameters | Bio-Rad Laboratories Inc | Thermo Fisher Scientific Inc | Abbott Laboratories | Siemens Healthineers AG | Danaher Corp |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Germany | United States of America |
| City | Hercules | Waltham | Abbott Park | Forchheim | Washington |
| State/Province | California | Massachusetts | Illinois | Bayern | WashingtonD.C. |
| No. of Employees | 7,450 | 125,000 | 115,000 | 72,000 | 58,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Norman D. Schwartz | Chairman; Chief Executive Officer | Executive Board | 2012 | 76 |
| Roop K. Lakkaraju | Executive Vice President; Chief Financial Officer | Senior Management | 2024 | 55 |
| Jonathan P. DiVincenzo | President; Chief Operating Officer | Senior Management | 2024 | 60 |
| Eva Anette Engelhardt | President - Clinical Diagnostics Group; Executive Vice President | Senior Management | 2024 | 56 |
| James J. Barry | Executive Vice President; President - Life Science Group | Senior Management | 2024 | 48 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer